Phosphorylation-dependent protein-protein interaction modules as potential molecular targets for cancer therapy

Current Drug Targets

Volumn 13, Issue 13, 2012, Pages 1654-1658

  Watanabe, Nobumoto ^a   Osada, Hiroyuki ^a  

^a RIKEN   (Japan)

Author keywords

High throughput screening; Plk1; Polo box domain; Protein phosphorylation; Protein protein interaction; Purpurogallin; Small molecule

Indexed keywords

BRCA1 PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; LEUCINE; PHOSPHOSERINE; PHOSPHOTHREONINE; POLO LIKE KINASE 1; POLO LIKE KINASE 2; POLO LIKE KINASE 3; PROTEIN 14 3 3; SERINE; THREONINE;

ARTICLE; CANCER THERAPY; GENE MUTATION; HIGH THROUGHPUT SCREENING; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN INTERACTION MAPS; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION;

EID: 84870159400     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012803530035     Document Type: Article

References (40)

1. Yaffe MB. Phosphotyrosine-binding domains in signal transduction. Nat Rev Mol Cell Biol 2002; 3: 177-186.
2. Yaffe MB, Elia AE. Phosphoserine/threonine-binding domains. Curr Opin Cell Biol 2001; 13: 131-138.
3. Watanabe N, Sekine T, Takagi M, et al. Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition. J Biol Chem 2009; 284: 2344-2353.
4. Muslin AJ, Tanner JW, Allen PM, Shaw AS. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 1996; 84: 889-897.
5. Yaffe MB, Rittinger K, Volinia S, et al. The structural basis for 14- 3-3:phosphopeptide binding specificity. Cell 1997; 91: 961-971.
6. Liu D, Bienkowska J, Petosa C, Collier RJ, Fu H, Liddington R. Crystal structure of the zeta isoform of the 14-3-3 protein. Nature 1995; 376: 191-194.
7. Xiao B, Smerdon SJ, Jones DH, et al. Structure of a 14-3-3 protein and implications for coordination of multiple signalling pathways. Nature 1995; 376: 188-191.
8. Vercoutter-Edouart AS, Lemoine J, Le Bourhis X, et al. Proteomic analysis reveals that 14-3-3sigma is down-regulated in human breast cancer cells. Cancer Res 2001; 61: 76-80.
9. Ferguson AT, Evron E, Umbricht CB, et al. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 2000; 97: 6049-6054.
10. Hermeking H, Lengauer C, Polyak K, et al. 14-3-3 sigma is a p53- regulated inhibitor of G2/M progression. Mol Cell 1997; 1: 3-11.
11. Clark GJ, Drugan JK, Rossman KL, et al. 14-3-3 zeta negatively regulates raf-1 activity by interactions with the Raf-1 cysteine-rich domain. J Biol Chem 1997; 272: 20990-20993.
12. Sugiyama A, Miyagi Y, Komiya Y, et al. Forced expression of antisense 14-3-3beta RNA suppresses tumor cell growth in vitro and in vivo. Carcinogenesis 2003; 24: 1549-1559.
13. Callebaut I, Mornon JP. From BRCA1 to RAP1: a widespread BRCT module closely associated with DNA repair. FEBS Lett 1997; 400: 25-30.
14. Manke IA, Lowery DM, Nguyen A, Yaffe MB. BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science 2003; 302: 636-639.
15. Shiozaki EN, Gu L, Yan N, Shi Y. Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling. Mol Cell 2004; 14: 405-412.
16. Clapperton JA, Manke IA, Lowery DM, et al. Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer. Nat Struct Mol Biol 2004; 11: 512-518.
17. Hofmann K, Bucher P. The FHA domain: a putative nuclear signaling domain found in protein kinases and transcription factors. Trends Biochem Sci 1995; 20: 347-349.
18. Liao H, Byeon IJ, Tsai MD. Structure and function of a new phosphopeptide- binding domain containing the FHA2 of Rad53. J Mol Biol 1999; 294: 1041-1049.
19. Durocher D, Taylor IA, Sarbassova D, et al. The molecular basis of FHA domain:phosphopeptide binding specificity and implications for phospho-dependent signaling mechanisms. Mol Cell 2000; 6: 1169-1182.
20. Tauchi H, Matsuura S, Isomura M, et al. Sequence analysis of an 800-kb genomic DNA region on chromosome 8q21 that contains the Nijmegen breakage syndrome gene, NBS1. Genomics 1999; 55: 242-247.
21. Bell DW, Kim SH, Godwin AK, et al. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer 2007; 121: 2661-2667.
22. Bell DW, Varley JM, Szydlo TE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999; 286: 2528-2531.
23. Deshaies RJ. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 1999; 15: 435-467.
24. Wu G, Xu G, Schulman BA, Jeffrey PD, Harper JW, Pavletich NP. Structure of a _-TrCP1-Skp1-_-catenin complex: destruction motif binding and lysine specificity of the SCF(_-TrCP1) ubiquitin ligase. Mol. Cell 2003; 11: 1445-1456.
25. Hao B, Zheng N, Schulman BA, et al. Structural basis of the Cks1- dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase. Mol Cell 2005; 20: 9-19.
26. Kitagawa M, Hatakeyama S, Shirane M, et al. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin. EMBO J 1999; 18: 2401-2410.
27. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6: 321-330.
28. Barr FA, Sillje HH, Nigg EA. Polo-like kinases and the orchestration of cell division. Nature Rev. Mol. Cell Biol 2004; 5: 429-440.
29. van Vugt MA, Medema RH. Getting in and out of mitosis with Polo-like kinase-1. Oncogene 2005; 24: 2844-2859.
30. Hudson JW, Kozarova A, Cheung P, et al. Late mitotic failure in mice lacking Sak, a polo-like kinase. Curr Biol 2001; 11: 441-446.
31. Seong YS, Kamijo K, Lee JS, et al. A spindle checkpoint arrest and a cytokinesis failure by the dominant-negative polo-box domain of Plk1 in U-2 OS cells. J Biol Chem 2002; 277: 32282-32293.
32. Elia AEH, Cantley LC, Yaffe MB. Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. Science 2003; 299: 1228-1231.
33. Elia AEH, Rellos P, Haire LF, et al. The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell 2003; 115: 83-95.
34. Hanisch A, Wehner A, Nigg EA, Sillje HH. Different Plk1 functions show distinct dependencies on Polo-Box domain-mediated targeting. Mol Biol Cell 2006; 17: 448-459.
35. Nagai T, Ibata K, Park ES, Kubota M, Mikoshiba K, Miyawaki A. A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. Nat Biotechnol 2002; 20: 87-90.
36. Watanabe N, Arai H, Iwasaki J, et al. Cyclin-dependent kinase (CDK) phosphorylation destabilizes somatic Wee1 via multiple pathways. Proc Natl Acad Sci USA 2005; 102: 11663-11668.
37. Tomiki T, Saito T, Ueki M, et al. RIKEN natural products encyclopedia.(RIKEN NPEdia), a chemical database of RIKEN natural products depository (RIKEN NPDepo). J Comp Aid Chem 2006; 7: 157-162.
38. Lane HA, Nigg EA. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 1996; 135: 1701-1713.
39. Murugan RN, Park JE, Kim EH, et al. Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity. Mol Cells 2011; 32: 209-220.
40. Liao C, Park JE, Bang JK, Nicklaus MC, Lee KS. Exploring Potential Binding Modes of Small Drug-like Molecules to the Polo-Box Domain of Human Polo-like Kinase 1. ACS Med Chem Lett 2010; 1: 110-114.